NON-INVASIVE MOLECULAR IMAGING OF INFLAMMATION IN TISSUE-ENGINEERED VASCULAR GRAFTS USING 18F-FDG PET/CT

2020 ◽  
Vol 75 (11) ◽  
pp. 1768
Author(s):  
Rosamaria Tricarico ◽  
Ting-Heng Chou ◽  
Susan Natalie Eisert ◽  
James Reinhardt ◽  
Kejal Shah ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Fdg Pet ◽  
Vascular Grafts ◽  
Non Invasive ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Molecular Imaging with 18F-FDG PET/CT and 99mTc-MIBI SPECT/CT in Osteitis Fibrosa Cystica Generalisata

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1355
Author(s):  
Adrien Holzgreve ◽  
Matthias P. Fabritius ◽  
Thomas Knösel ◽  
Lena M. Mittlmeier ◽  
Johannes Rübenthaler ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Fdg Pet ◽  
Correct Diagnosis ◽  
Osteitis Fibrosa ◽  
Osteitis Fibrosa Cystica ◽  
Pet Ct ◽  
Brown Tumors ◽  
18F Fdg ◽  
99Mtc Mibi ◽  
Fdg Pet Ct

Benign so-called “brown tumors” secondary to hyperparathyroidism are a rare diagnostic pitfall due to their impressively malignant-like character in various imaging modalities. We present the case of a 65-year-old male patient with multiple unclear osteolytic lesions on prior imaging suspicious for metastatic malignant disease. Eventually, findings of 18F-FDG PET/CT staging and 99mTc-MIBI scintigraphy resulted in revision of the initially suspected malignant diagnosis. This case illustrates how molecular imaging findings non-invasively corroborate the correct diagnosis of osteitis fibrosa cystica generalisata with the formation of multiple benign brown tumors.

scholarly journals FDG-PET/CT in predicting aggressiveness of rectal cancer

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Iman Sherif Ahmed ◽  
Saher Mohamed El Gaafary ◽  
Remon Zaher Elia ◽  
Rasha S. Hussein
Keyword(s):  
Rectal Cancer ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Tumour Progression ◽  
Treatment Plan ◽  
Complete Regression ◽  
Non Invasive ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Background Treatment response varies significantly among rectal cancer patients. Tumor can show complete regression, stationary appearance, or even tumour progression during the treatment. It is also widely known that the rate of local recurrence is variable. Precise risk stratification of tumor aggressiveness is required for better per patient tailored treatment plan and predicting the overall prognosis of rectal cancer patients The aim of this study was to assess different parameters of baseline [18F] fluorodeoxyglucose positron emission tomography/computed tomography [(18F) FDG-PET/CT] as a non-invasive tool in predicting aggressiveness of the rectal cancer. Results Overall, 33 patients were included [19 moderately differentiated adenocarcinoma, 10 poorly differentiated adenocarcinoma and 4 mucinous adenocarcinomas (MAC)]. SUV estimates (SUV max, SUV mean) were greater in the moderately adenocarcinoma group (p = 0.003 and p = 0.019, respectively). MTV and TLG values were similar between the three histopathological groups (p = 0.763 and p = 0.701, respectively). There was no correlation between SUVmax of primary tumor and MTV (r = 0.034; p = 0.849). However, SUVmax and TLG were significantly correlated (r = 0.517; p = 0.002). Strong correlation between tumor size and MTV (r = 0.489; p = 0.003), and TLG (r = 0.506; p = 0.003) were observed. No significant association was found between MTV and TLG and the clinical stage of rectal cancer. Conclusion Baseline 18F-FDG PET/CT parameters cannot be used alone as a non-invasive diagnostic technique in assessing aggressiveness and prognosis in patients with primary rectal cancer, and further clinical studies are needed before considering the prognostic role of FDG-PET/CT in rectal cancer.

scholarly journals Recommendations of the Spanish Societies of Radiation Oncology (SEOR), Nuclear Medicine & Molecular Imaging (SEMNiM), and Medical Physics (SEFM) on 18F-FDG PET-CT for radiotherapy treatment planning

2012 ◽  
Vol 17 (6) ◽  
pp. 298-318 ◽  
Author(s):  
Begoña Caballero Perea ◽  
Antonio Cabrera Villegas ◽  
José Miguel Delgado Rodríguez ◽  
María José García Velloso ◽  
Ana María García Vicente ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Molecular Imaging ◽  
Radiation Oncology ◽  
Fdg Pet ◽  
Medical Physics ◽  
Radiotherapy Treatment Planning ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Radiotherapy Treatment

18F-FDG PET/CT for Molecular Imaging of Hepatoblastoma in Beckwith-Wiedemann Syndrome

2018 ◽  
Vol 43 (5) ◽  
pp. e164-e165
Author(s):  
Thorsten Derlin ◽  
Dagmar Hartung ◽  
Katja Hueper
Keyword(s):  
Molecular Imaging ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Improved non-invasive T-Staging in non-small cell lung cancer by integrated18F-FDG PET/CT

2007 ◽  
Vol 46 (01) ◽  
pp. 09-14 ◽  
Author(s):  
S. Pauls ◽  
A. K. Buck ◽  
K. Hohl ◽  
G. Halter ◽  
M. Hetzel ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Tumor Stage ◽  
Small Cell ◽  
Imaging Modalities ◽  
Small Cell Lung ◽  
Non Invasive ◽  
T Stage ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Summary Aim: In this prospective study, reliability of integrated 18F-FDG PET/CT for staging of NSCLC was evaluated and compared to MDCT or PET alone. Patients, methods: 240 patients (pts) with suspected NSCLC were examined using PET/CT. Of those patients 112 underwent surgery comprising 80 patients with NSCLC (T1 n = 26, T2 n = 37, T3 n = 11, T4 n = 6). Imaging modalities were evaluated independently. Results: MDCT, PET and PET/CT diagnosed the correct T-stage in 40/80 pts (50%; CI: 0.39-0.61), 40/80 pts (50%; CI: 0.39-0.61) and 51/80 pts (64%; CI: 0.52-0.74), respectively, whereas equivocal T-stage was found in 15/80 pts (19%; CI: 0.11-0.19), 12/80 pts (15%; CI: 0.08-0.25) and 4/80 pts (5%; CI: 0.01-0.12), respectively. With PET/CT, T-stage was more frequently correct compared to MDCT (p = 0.003) or PET (p = 0.019). Pooling stages T1/T2, T-stage was correctly diagnosed with MDCT, PET and PET/CT in 54/80 pts (68%; CI: 0.56-0.78), 56/80 pts (70%; CI: 0.59-0.80) and 65/80 pts (81%; CI: 0.71-0.89). T3 stage was most difficult to diagnose. T3 tumors were correctly diagnosed with MDCT in 2/11 pts (18%; CI: 0.02-0.52) versus 0/11 pts (0%; CI: 0.00-0.28) with PET and 5/11 pts (45%; CI: 0.17-0.77) with PET/CT. In all imaging modalities, there were no equivocal findings for T4 tumors. Of these, MDCT found the correct tumor stage in 4/6 pts (67%; CI: 0.22-0.95), PET in 3/6 pts (50%; CI: 0.12-0.88) and PET/ CT in 5/6 pts (83%; CI: 0.36-0.99). Conclusion: Integrated PET/CT was significantly more accurate for T-staging of NSCLC compared to MDCT or PET alone. The advantages of PET/CT are especially pronounced combining T1- and T2-stage as well as in advanced tumors.

scholarly journals Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias

Oncotarget ◽  
2020 ◽  
Vol 11 (6) ◽  
pp. 589-599
Author(s):  
Ioannis Karfis ◽  
Gwennaëlle Marin ◽  
Hugo Levillain ◽  
Stylianos Drisis ◽  
Raoul Muteganya ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Grading System ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document